Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Many biological effects of taurine rely upon its cellular concentration, which is primarily controlled by taurine biosynthetic enzymes
cysteine dioxygenase
(
CDO
) and cysteine sulfinate decarboxylase (CSD) and taurine transporter (TauT). The cloning of
CDO
, CSD and TauT in various species provided first-hand information on these proteins, as well as molecular tools to investigate their regulations.
CDO
upregulation in hepatocytes in response to high sulfur amino acids appears clearly as the most spectacular among the regulations of the biosynthetic enzymes. Downregulation of TauT activity by activation of PKC appears particularly well documented. A unique serine residue could be identified as a phosphorylation site that leads to an inactive form of TauT. The previously revealed downregulation of TauT expression by taurine and hypertonicity-induced upregulation of TauT expression were shown to result from a modified transcription rate of TauT gene, but the precise molecular mechanisms are not yet formally established. Other regulations of taurine transporter expression were more recently reported, which involve glucose,
tumor suppressor protein p53
, tumor necrosis factor-alpha, and nitric oxide. This review reports the experimental models and data that support these various regulations but also points out the aspects that remain poorly understood or unknown concerning their molecular basis and physiological significance.
...
PMID:Taurine biosynthetic enzymes and taurine transporter: molecular identification and regulations. 1499 66